Histatin 5 Metallopeptides and Their Potential against Candida albicans Pathogenicity and Drug Resistance

Usually caused by Candida albicans, buccal candidiasis begins with the morphological transition between yeast and hyphal cells. Over time and without the correct treatment, it can be disseminated through the bloodstream becoming a systemic infection with high mortality rates. C. albicans already shows resistance against antifungals commonly used in treatments. Therefore, the search for new drugs capable of overcoming antifungal resistance is essential. Histatin 5 (Hst5) is an antimicrobial peptide of the Histatin family, that can be found naturally in human saliva. This peptide presents high antifungal activity against C. albicans. However, Hst5 action can be decreased for interaction with enzymes and metal ions present in the oral cavity. The current work aims to bring a brief review of relevant aspects of the pathogenesis and resistance mechanisms already reported for C. albicans. In addition, are also reported here the main immune responses of the human body and the most common antifungal drugs. Finally, the most important aspects regarding Histatin 5 and the benefits of its interaction with metals are highlighted. The intention of this review is to show the promising use of Hst5 metallopeptides in the development of effective drugs.

In vitro and in silico assessment of antitumor properties and biomolecular binding studies for two new complexes based on NiII bearing k2N,S-donor ligands

This work deals with two new molecule-based materials, namely Ni^II-complexes of general formulae [Ni(L1)₂] (Ni1) and [Ni(L2)₂] (Ni2), where L1 = trans-cinnamaldehyde-N(4)-methyl thiosemicarbazone and L2 = trans-cinnamaldehyde-N(4)-ethyl thiosemicarbazone, as potential antitumor agents. Both compounds were characterized by elemental analysis, molar conductivity and spectroscopic techniques (FTIR and NMR). Their molecular structures were obtained by single-crystal X-ray diffraction analysis. Each one crystallizes in a monoclinic space group P 2₁/c, also the asymmetric unit comprises of one Ni^II ion located on an inversion centre and one anionic ligand, which acts as a κ²N,S-donor affording a five-membered metallaring. The compounds were screened against two selected tumour cell lines (MCF-7 and A549) and non-tumour fibroblasts cell line (MRC-5) via MTT assays. In both tumour cells, all compounds exhibited higher cytotoxicity than the control drug (cisplatin). The IC₅₀ values ranges of 3.70 - 41.37 μM and 1.06 - 14.91 μM were found for MCF-7 and A549, respectively. Importantly, all of them were less toxicity than cisplatin in MRC-5 with SI values ranged at 11.80 - 86.60. The red blood cell (RBC) assay revealed Ni2 as non-toxic due to its reduced haemolytic effect (0--9% at 1--10 μM). The DNA binding was investigated through a combination of spectrophotometric absorption and emission titrations, electrophoresis, and circular dichroism experiments. As a result, these metal complexes were not able to strongly binding to DNA (K_b values ~10⁴ mol L^--1) but suggesting groove-binding interactions. The scavenging ability of them towards 2,2-diphenyl-1-picrylhydrazyl (DPPH) free-radical was also evaluated in this work, but no important antioxidant behaviour was detected. Further, the interaction of Ni1 and Ni2 to human serum albumin (HSA) was explored by quenching of tryptophan emission, warfarin competitive assay, and molecular docking protocols. The HSA binding analyses indicated good affinity of both complexes to Sudlow site I (K_b values ⁓10³ mol L^-1).

Avaliação quantitativa da susceptibilidade do crescimento de Staphylococcus aureus na presença de sistemas antimicrobianos de alta complexidade

Antimicrobial peptides (PAMs) found naturally in living organisms are a great promise for the fight against infectious diseases specially by microorganisms multiresistant to the commercial antibiotics available on the market due to intensive and inadequate applying of those substances. However, some particular characteristics that may be present in PAMs (big size, low solubility, the existence of effective load, high structural complexity, etc.) pose difficulty vis-à-vis the use of this class of substances for clinical application. As an approach to solve this technical barrier to application of PAMs, different formulations of LUV liposomes were prepared with the intent to promote the encapsulation of CcdBET2, a proven PAM, and promote its delivery in the intracellular environment. CcdBET2 was synthesized by solid-phase methodology and the 100 nm liposomes by extrusion. The peptide-liposomes systems were tested against Staphylococcus aureus by a quantitative methodology using MTT to test their ability in promote the interruption of cell growth. It is possible to suggest that the liposomal system is responsible to interact with the bacterial membrane allowing CcdBET2 to exert its antimicrobial activity.